ELDN
Price
$2.99
Change
-$0.01 (-0.33%)
Updated
Apr 17 closing price
Capitalization
179.05M
20 days until earnings call
MREO
Price
$2.30
Change
+$0.17 (+7.98%)
Updated
Apr 17 closing price
Capitalization
365.7M
26 days until earnings call
Ad is loading...

ELDN vs MREO

Header iconELDN vs MREO Comparison
Open Charts ELDN vs MREOBanner chart's image
Eledon Pharmaceuticals
Price$2.99
Change-$0.01 (-0.33%)
Volume$143.75K
Capitalization179.05M
Mereo BioPharma Group
Price$2.30
Change+$0.17 (+7.98%)
Volume$2.26M
Capitalization365.7M
ELDN vs MREO Comparison Chart
Loading...
ELDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELDN vs. MREO commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELDN is a Hold and MREO is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (ELDN: $2.99 vs. MREO: $2.30)
Brand notoriety: ELDN and MREO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELDN: 63% vs. MREO: 152%
Market capitalization -- ELDN: $179.05M vs. MREO: $365.7M
ELDN [@Biotechnology] is valued at $179.05M. MREO’s [@Biotechnology] market capitalization is $365.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELDN’s FA Score shows that 1 FA rating(s) are green whileMREO’s FA Score has 1 green FA rating(s).

  • ELDN’s FA Score: 1 green, 4 red.
  • MREO’s FA Score: 1 green, 4 red.
According to our system of comparison, ELDN is a better buy in the long-term than MREO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELDN’s TA Score shows that 5 TA indicator(s) are bullish while MREO’s TA Score has 5 bullish TA indicator(s).

  • ELDN’s TA Score: 5 bullish, 3 bearish.
  • MREO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ELDN and MREO are a good buy in the short-term.

Price Growth

ELDN (@Biotechnology) experienced а +5.65% price change this week, while MREO (@Biotechnology) price change was +25.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

ELDN is expected to report earnings on Aug 07, 2025.

MREO is expected to report earnings on Oct 07, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MREO($366M) has a higher market cap than ELDN($179M). ELDN YTD gains are higher at: -27.427 vs. MREO (-34.286). MREO has higher annual earnings (EBITDA): -43.41M vs. ELDN (-55.85M). MREO (80.5M) and ELDN (78.2M) have equal amount of cash in the bank . ELDN has less debt than MREO: ELDN (501K) vs MREO (6.68M). MREO has higher revenues than ELDN: MREO (1M) vs ELDN (0).
ELDNMREOELDN / MREO
Capitalization179M366M49%
EBITDA-55.85M-43.41M129%
Gain YTD-27.427-34.28680%
P/E Ratio4.81N/A-
Revenue01M-
Total Cash78.2M80.5M97%
Total Debt501K6.68M7%
FUNDAMENTALS RATINGS
ELDN vs MREO: Fundamental Ratings
ELDN
MREO
OUTLOOK RATING
1..100
1415
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
10069
SMR RATING
1..100
1795
PRICE GROWTH RATING
1..100
5587
P/E GROWTH RATING
1..100
742
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ELDN's Valuation (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for MREO (77) in the null industry. This means that ELDN’s stock grew somewhat faster than MREO’s over the last 12 months.

MREO's Profit vs Risk Rating (69) in the null industry is in the same range as ELDN (100) in the Pharmaceuticals Major industry. This means that MREO’s stock grew similarly to ELDN’s over the last 12 months.

ELDN's SMR Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for MREO (95) in the null industry. This means that ELDN’s stock grew significantly faster than MREO’s over the last 12 months.

ELDN's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as MREO (87) in the null industry. This means that ELDN’s stock grew similarly to MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for ELDN (74) in the Pharmaceuticals Major industry. This means that MREO’s stock grew significantly faster than ELDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELDNMREO
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ELDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFESX47.540.41
+0.87%
Janus Henderson European Focus S
RVPIX7.150.03
+0.42%
Royce Smaller-Companies Growth Instl
FRGOX23.62N/A
N/A
Franklin Gold and Precious Metals C
ITCSX27.40N/A
N/A
VY® T. Rowe Price Capital Apprec S
MFMLX13.85N/A
N/A
Morgan Stanley Inst Next Gen Em Mkts L

ELDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELDN has been loosely correlated with SYRE. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ELDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELDN
1D Price
Change %
ELDN100%
-0.33%
SYRE - ELDN
35%
Loosely correlated
+2.01%
ATOS - ELDN
35%
Loosely correlated
+2.99%
CDXS - ELDN
35%
Loosely correlated
-0.47%
ZURA - ELDN
33%
Poorly correlated
+6.96%
AMLX - ELDN
33%
Poorly correlated
+4.19%
More

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with VKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
+7.98%
VKTX - MREO
43%
Loosely correlated
+1.44%
TERN - MREO
42%
Loosely correlated
+7.14%
CRNX - MREO
41%
Loosely correlated
+2.84%
TRDA - MREO
41%
Loosely correlated
+3.44%
ACLX - MREO
40%
Loosely correlated
+2.19%
More